A multicenter, randomized placebo controlled pilot microCT study to estimate the effect of treatment with denosumab (AMG 162) and alendronate sodium in postmenopausal women with low bone mineral density.
Latest Information Update: 30 Mar 2022
At a glance
- Drugs Denosumab (Primary) ; Alendronic acid
- Indications Bone resorption; Fracture; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Amgen
- 02 Apr 2014 Results comparing trabecular bone score and bone mineral density presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
- 08 Oct 2013 Results assessing bone measures at the lumbar spine, including the trabecular bone score, presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
- 16 Oct 2012 Results assessing effects of treatment on trabecular bone volume fraction and intracortical porosity presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.